|Bid||5.01 x 1800|
|Ask||4.90 x 800|
|Day's Range||4.42 - 5.08|
|52 Week Range||3.34 - 22.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.75|
Ra Medical Systems, Inc. today announced the schedule of key DABRA Excimer Laser Atherectomy events at the upcoming Charing Cross International Symposium in London April 16–18.
Introduces new integrated commercial strategy to support physician adoption of the DABRA laser system and build long-term customer relationshipsConference call begins at 4:30 pm Ea
Ra Medical Systems, Inc. , today announced study results from Athar Ansari, MD, Director of the California Heart & Vascular Clinic, who stated, “DABRA is fundamentally changing the way I practice medicine.” Dr.
Ra Medical Systems, Inc. announces that it will report 2018 fourth quarter and full year financial results after market close on Thursday, March 14, 2019. Ra Medical management will hold an investment community conference call at 4:30 p.m.
The study results were overwhelmingly positive, given the inclusion of a challenging sample of patients, all Rutherford class 4 to 6 with a high presence of calcium (80% of lesions had moderate to severe calcification) and 93% median lesion stenosis. “The results of this study are extremely promising and demonstrate the positive clinical outcomes we have seen with DABRA,” said Dr. Kondur, Chair, Division of Cardiology, Garden City Hospital/MSU and Associate Program Director, Interventional Cardiology Fellowship Program, DMC Harper University Hospital, Wayne State University.
Ra Medical Systems, Inc. (RMED), a medical device company focusing on commercializing excimer laser systems to treat tough vascular and dermatological diseases, announces that CEO Dean Irwin will present at the 11th Annual Biotech Showcase on January 8, 2019, in San Francisco. Mr. Irwin will present an overview of Ra Medical’s business, technology and strategic growth objectives, including the commercialization of its excimer laser system, DABRA™, which is FDA-cleared to cross chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease.
Ra Medical Systems, Inc.'s (NYSE:RMED): Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. Read More...
Mr. Fogarty brings over two decades of medical device leadership and commercialization experience to Ra Medical Systems and will oversee all aspects of the Company's commercialization efforts, which include the sales and marketing of its proprietary excimer laser systems that treat tough vascular and dermatological diseases. “Over the years, Tom has demonstrated a proven track record leading both early-stage companies and large corporations through commercialization and sales growth,” said Dean Irwin, Chief Executive Officer, Ra Medical Systems.
Ra Medical Systems, Inc. (RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases, announced that it will release its financial results for the three-month period ended September 30, 2018 on Tuesday, November 13, 2018 after the market close. The Company will host a conference call with the investment community on Tuesday, November 13th, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time featuring remarks by Dean Irwin, Chief Executive Officer and Andrew Jackson, Chief Financial Officer. The dial-in numbers for the conference call are +1-877-407-4018 (U.S. Toll Free) or +1-201-689-8471 (International).
Ra Medical Systems, Inc. (RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases, announced today that it has appointed Dan Horwood as General Counsel, effective immediately. Mr. Horwood brings nearly two decades of corporate and securities experience to Ra Medical and will oversee all aspects of the Company’s legal activities and policies. “Dan’s deep experience advising publicly listed companies on corporate matters makes him an ideal and timely choice for Ra Medical.
Ra Medical Systems, Inc. today announced the closing of its initial public offering of 4,485,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase 585,000 additional shares of its common stock, at a price to the public of $17 per share.
Ra Medical Systems, Inc. (RMED) today announced the pricing of its initial public offering of 3,900,000 shares of common stock at a price to the public of $17.00 per share. In addition, Ra Medical has granted the underwriters a 30-day option to purchase up to an additional 585,000 shares of common stock at the initial public offering price less underwriting discounts and commissions. Ra Medical’s common stock is expected to begin trading on the New York Stock Exchange under the symbol “RMED” on September 27, 2018.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...